Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IMO , GE is going to try to buy up Biotricity. You heard it here first. Think it’s leaked out and that explains the volume and the call volume that has been bought up recently.It makes sense because GE is trying to do the same thing as Philips, and get into the cardiac and peripheral space.
For all wondering what’s up, here it is , earning early November, which will be great and FDA approval in November. Remember you heard it here first
REDWOOD CITY, CA / ACCESSWIRE / September 8, 2021 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today reported its CEO Waqaas Al-Siddiq is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference, which will be available on-demand starting at 7:00 a.m. ET on Monday, September 13, 2021 (details provided below).
Dr. Al-Siddiq will discuss the Company's continuing sales growth of its FDA-approved Bioflux® mobile cardiac telemetry (MCT) device which, as the Company previously announced, drove its FY22-1Q revenue up 290% YOY and approximately 49% sequentially. He will also discuss sales expansion and the company's planned product portfolio that the Company believes will increase the current total addressable market (TAM) while growing revenues. As previously announced, Biotricity recently completed a $15 million equity raise and listed on the Nasdaq Capital Market.
The presentation will be available to registered attendees from Monday, September 13 to Wednesday, September 15.
I agree . More buys than sales today and prices drops , must be taking out all and any stop losses
Earnings is out, check out the release. Some of the positive highlights:
* Q4 revenue of $1.2M (up from $1.0M last quarter)
* Quarterly revenue increased 227% (162% increase posted in prior quarter)
* Annual revenue of $3.4M (increase of 139% over fiscal 2020)
* Gross operating expenses grew at slower pace than revenue in Q4
AUSTIN, Texas, March 16, 2021 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Waqaas Al-Siddiq, CEO of Biotricity Inc. (OTCQB: BTCY) (“the Company”), a modern medical technology company delivering disruptive solutions to the multi-billion-dollar cardiac monitoring and diagnostic market.
Biotricity’s flagship Bioflux® product is a wearable medical device that enables physicians to accurately monitor and diagnose cardiac patients in real-time for effective treatment and pain management. While this technology alone targets a massive demographic, the Company’s full pipeline of remote cardiac monitoring and diagnostic solutions provides access to a multi-billion-dollar market hungry for digital innovation.
Speaking with SCV’s Stuart Smith, Dr. Al-Siddiq describes how Biotricity builds and delivers its technology to benefit patients, care providers and the broader healthcare industry, while building long-term value for the Company.
“What we’ve noticed primarily across healthcare, is that technology is owned by clinical players – players that are actually performing the diagnostic tests,” he says. “Our model is very different. We want to enable physicians, hospitals and organizations to do that work so we can stay focused on things of a technology company.”
Biotricity’s monitoring devices are built in-house and are reusable, which saves on costs and enables exponential revenue growth through a recurring technology fee and greater market reach.
“That’s where we have been really fortunate to have a cycle of growth over growth,” explains Dr. Al-Siddiq. “We have a sales force, and the idea is for us to continue to open up more clinics, more hospitals, and get our devices into more hands.”
Biotricity currently has a sales presence in 20 U.S. states. Near-term growth plans include launching more products from the Company’s pipeline and expanding its sales force to target a larger addressable market.
“The most successful medical device and pharma companies have a direct sales force in their key markets and then they have distribution elsewhere,” says Dr. Al-Siddiq. “We are following the exact same track.”
Dr. Al-Siddiq also highlights the experience of Biotricity’s staff and how it was able to leverage that expertise to stride through the challenges of the pandemic and meet demand for remote monitoring.
“Intelligent monitoring and the value of it became very, very clear because of the pandemic,” he says. “The awareness and the need for it increased. The ability to sell was of course limited, but despite that, we were able to grow … Once this pandemic is more under control, I think it’s going to actually crate a boost in our growth in the long term.”
As the Company ramps up its sales force, it is also focused on the release of a new product and uplisting to a national exchange for greater visibility. Of significance, says Dr. Al-Siddiq, is for investors to remember Biotricity’s application to the healthcare industry and how that affects revenues.
“We are a technology company, not a clinical company,” he tells Smith. “Our focus is providing technology to physicians and healthcare companies in a business model that is anchored in reimbursement and a reoccurring revenue model. That is something that creates and accelerated growth and gives us a very high value long term. Being a technology player with a reoccurring business model places us at the top of the food chain when it comes to how to value the company. And we’ve done that in a very specific and concerted way.”
The full interview can be heard at: https://www.smallcapvoice.com/interview-biotricity-btcy/.
Biocare Telemed is a virtual clinic platform with secure HIPPA compliant technology.
The platform enables clinicians to provide outstanding patient care remotely, ensuring at-risk patients and those needing remote cardiac monitoring do not have to leave the safety of their home. The user-friendly platform ensures seamless integration in to the clinics’ current workflow, saving time and reducing costs.
For the patients this means:
Convenient appointment booking
Access when and where needed
Avoid time-off work
Skip the waiting room
Avoid catching an illness
Reduce the anxiety
Bioflux® is a high-precision, single-unit mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of your ambulatory patients’ ECG information. The Bioflux® system is a complete solution for remote cardiac monitoring that merges seamlessly with physicians’ existing platforms and workflows.
We track over 100 billion heartbeats a year, monitored in real-time by our certified cardiac technicians with unmatched reporting capabilities.
Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and ?lifestyle improvement
REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it made a 510(k) submission to the U.S. Food and Drug Administration (FDA), on December 31 2020, for Biotres. The company expects this process to take at least 4 months, and if the Company’s 510(k) application is cleared by the FDA the Company expects a product launch thereafter.
As announced previously, Biotres is a 3-lead patch product for ECG and arrhythmia monitoring for patients at risk for or being diagnosed with certain cardiac issues. Biotres can work as a Holter, Event Loop, and Extended Holter.
“We are excited to announce the 510(k) FDA submission for Biotres and look forward to building out our product offerings further in 2021,” stated Waqaas Al Siddiq, CEO of Biotricity. “We believe that Biotres addresses demand from some of our existing customers and a need in the holter market.”
The Biotres is a holter product that was developed to address the challenges that exist with current holter patch products. The Biotres is designed with the following key features:
3 Channel Recording – A wearable holter patch device that can provide continuous 3 channel recording of ECG (heart) data. All other holter patch devices are 1 channel or 2 channels.
Rechargeable Battery – The device can be worn continuously for 48 hours, before needing to be charged for 1 hr., enabling continuous data collection for extended periods of time without any intervention, something not possible with traditional holter patch solutions.
Wireless Connectivity – The unique device utilizes Bluetooth technology to offload data, reducing the time for diagnoses. Current holter patch solutions can take up to a week before diagnoses are available due to manual data downloading and a lack of connectivity.
User-Friendly Design – Easy to understand and comfortable to wear during regular day-to-day activities.
FDA should push price past 4.50
Under valued stock , just starting to get noticed
Uplisting on the way
FDA approval on the way
Anyone following me , buy buy buy. Bsmx, San , bbar. Thank me later. Full disclosure, I own 3700 of bsmx. Long and short calls. I own 10 long calls of San strick price 2.00. 2031. I own 24 long calls of bbar April 2021 strick price 5.00 at . 45 cent . I own 3800. Shares of bbar.
5G First Responder Lab:
A Commitment to Public Safety.
The future of public safety technology will be powered by 5G networks. From critical communications, to situational awareness, to virtual reality, to drones; 5G will enable life saving capabilities that will empower the first responders who protect our communities. Verizon and ResponderXLabs are committed to delivering those vital capabilities as soon as possible. 5G First Responder Lab will help deliver that commitment by working alongside boots-on-the-ground to identify the most pressing needs, and the global entrepreneurial community to source the leading solutions. In 2019, 5G First Responder Lab will enable 15 emerging technologies with the power of 5G, and then we’ll deliver those solutions to public safety agencies throughout the country. No whitepapers, no hackathons. Real solutions, real deployments. 5G First Responder Lab will do more than just enable technology; we’ll make sure that technology is what first responders truly need, and we’ll make sure it’s available for every agency. That’s our commitment to public safety.
Program Benefits:
5G Enablement
Agency Sales Acceleration
Showcase Opportunities
Press & Demo Exposure
Pilot Opportunities
Potential Venture Investment
Potential Product Distribution
Biotricity(R) Partners with Verizon to Develop EMS Solutions
8:00 AM ET 7/14/20 | Dow Jones
Related Quotes
10:05 AM ET 7/14/20
Symbol Last % Chg
BTCY
1.59 4.61%
Real time quote.
Biotricity(R) Partners with Verizon to Develop EMS Solutions
Verizon to Integrate the Bioflux(R) Solution into their EMS and Launch to Existing and Future Customers
REDWOOD CITY, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company announced a strategic partnership with Verizon (NYSE: VZ) to develop EMS solutions for First Responders by integrating its Bioflux solution. Bioflux is a high-precision, single-unit mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of patients' ECG information. Integrating the Bioflux solution into Verizon's EMS platform realizes an unmet need for First Responders, enabling them to access critical, potentially life-saving data in real-time and respond immediately in a crisis.
"We at Biotricity are committed to developing innovative technology that provides healthcare workers and medical professionals the vital patient data they need. Collaboration with Verizon offers an exciting avenue for our team of experts to deliver frontline workers a device that provides remote patient diagnostics in real-time and potentially saves lives," said Spencer LaDow, VP of Research & Development.
First Responders require connectivity and specialized equipment to enable immediate response in a crisis. Biotricity's device provides continuous connectivity, real-time monitoring and diagnostic reporting that will be integrated into Verizon's current EMS platform, fulfilling an unmet need. Partnering with Verizon allows the company to fill this gap and access a new market while adding a revenue stream. Once integrated, Verizon will use its ecosystem and resources to bring the solution to market.
"Our technology is an obvious fit for a variety of markets, and it is a privilege to see it applied in vital health care areas such as First Responders. As a growing company, we have focused on the remote patient monitoring market but are aware of the potential in other markets for our solutions. Partnerships like this enable us to expand our opportunities, creating new revenue streams, while focusing on our core market," said Dr. Al-Siddiq, CEO of Biotricity.
To learn more about this partnership, read Verizon's Press Release here.
Join our newsletter at: https://www.biotricity.com/contact-us/ or follow on:
Twitter: @biotricity_inc
Facebook: facebook.com/biotricity/ or
LinkedIn: linkedin.com/company/biotricity-measuring-vitals
Verizon accelerates 5G-enabled EMS solutions with new cohort of its 5G First Responder Lab
Media contact(s)
Chris Ashraf
908-381-2384
christina.moon.ashraf@verizon.com
Najuma Thorpe
732.427.2304
najuma.thorpe@verizon.com
What you need to know:
Companies in fourth cohort will focus on 5G-enabled solutions to common challenges along the typical EMS/patient journey
5G’s fast speed, massive bandwidth and low latency could aid autonomous dispatch, tracking and monitoring and more
Applications now being considered for fifth cohort focusing on fire response and situational awareness
""
NEW YORK – As part of Verizon’s continued commitment to invest in public safety and support first responders, the company has chosen five companies to take part in the fourth cohort of its 5G First Responder Lab. The companies will work together to accelerate 5G development of solutions to common challenges along the EMS/patient journey from pre-incident and emergency response to treatment and recovery, all powered by Verizon’s 5G Ultra Wideband network.
“With the COVID-19 global pandemic, EMS workers on the frontlines are struggling with a heavy workload and oftentimes a lack of vital information at their fingertips,” said Andrés Irlando, senior vice president and president, Public Sector and Verizon Connect at Verizon. “Solutions built on Verizon’s 5G Ultra Wideband network will put critical information in the hands of EMS workers by enabling innovations like smart dispatching, non-emergent interventions, telehealth and remote diagnostics. We’re excited to see the potentially life-saving solutions developed by these innovators when given access to Verizon’s 5G Ultra Wideband network.”
The companies participating in this cohort include:
Biotricity: Focuses on near real-time remote medical monitoring
Rave Mobile Safety: Offers a critical communications and data sharing platform
DispatchHealth: Provides on-call medical care to your door
Vuzix: Uses augmented reality to better inform First Responders
Visionable: Provides a platform for near real-time medical collaboration
Over the next six months, these companies will have access to Verizon 5G specialists, engineers and Verizon’s 5G Ultra Wideband network to further develop their solutions using 5G’s high speed and ultra-low latency capabilities. The 5G First Responder Lab launched in November 2018 in partnership with Responder Corp. as a first-of-its-kind innovation program to identify promising technology companies, and give them access to 5G technology to test and refine their 5G solutions for public safety. The first three cohorts included 15 startups who tested their developments on 5G Ultra Wideband, including autonomous persistent drones for security and situational awareness, gun detection software using existing municipal cameras, computer vision heads up display for firefighters to see through smoke, and VR training for police officers and EMTs. Verizon continues to explore partnership opportunities with several of these startups.
Verizon is also now accepting applicants for the fifth cohort of its 5G First Responder Lab focused on fire response and situational awareness solutions. The fifth cohort participants will be selected in Q4 2020. Apply here.
Learn more about Verizon 5G Labs and Verizon 5G technology. View previous cohorts of the First Responder Lab by clicking on the Alumni tab here.
Tags:
Verizon accelerates 5G-enabled EMS solutions with new cohort of its 5G First Responder Lab
Media contact(s)
Chris Ashraf
908-381-2384
christina.moon.ashraf@verizon.com
Najuma Thorpe
732.427.2304
najuma.thorpe@verizon.com
What you need to know:
Companies in fourth cohort will focus on 5G-enabled solutions to common challenges along the typical EMS/patient journey
5G’s fast speed, massive bandwidth and low latency could aid autonomous dispatch, tracking and monitoring and more
Applications now being considered for fifth cohort focusing on fire response and situational awareness
""
NEW YORK – As part of Verizon’s continued commitment to invest in public safety and support first responders, the company has chosen five companies to take part in the fourth cohort of its 5G First Responder Lab. The companies will work together to accelerate 5G development of solutions to common challenges along the EMS/patient journey from pre-incident and emergency response to treatment and recovery, all powered by Verizon’s 5G Ultra Wideband network.
“With the COVID-19 global pandemic, EMS workers on the frontlines are struggling with a heavy workload and oftentimes a lack of vital information at their fingertips,” said Andrés Irlando, senior vice president and president, Public Sector and Verizon Connect at Verizon. “Solutions built on Verizon’s 5G Ultra Wideband network will put critical information in the hands of EMS workers by enabling innovations like smart dispatching, non-emergent interventions, telehealth and remote diagnostics. We’re excited to see the potentially life-saving solutions developed by these innovators when given access to Verizon’s 5G Ultra Wideband network.”
The companies participating in this cohort include:
Biotricity: Focuses on near real-time remote medical monitoring
Rave Mobile Safety: Offers a critical communications and data sharing platform
DispatchHealth: Provides on-call medical care to your door
Vuzix: Uses augmented reality to better inform First Responders
Visionable: Provides a platform for near real-time medical collaboration
Over the next six months, these companies will have access to Verizon 5G specialists, engineers and Verizon’s 5G Ultra Wideband network to further develop their solutions using 5G’s high speed and ultra-low latency capabilities. The 5G First Responder Lab launched in November 2018 in partnership with Responder Corp. as a first-of-its-kind innovation program to identify promising technology companies, and give them access to 5G technology to test and refine their 5G solutions for public safety. The first three cohorts included 15 startups who tested their developments on 5G Ultra Wideband, including autonomous persistent drones for security and situational awareness, gun detection software using existing municipal cameras, computer vision heads up display for firefighters to see through smoke, and VR training for police officers and EMTs. Verizon continues to explore partnership opportunities with several of these startups.
Verizon is also now accepting applicants for the fifth cohort of its 5G First Responder Lab focused on fire response and situational awareness solutions. The fifth cohort participants will be selected in Q4 2020. Apply here.
Learn more about Verizon 5G Labs and Verizon 5G technology. View previous cohorts of the First Responder Lab by clicking on the Alumni tab here.
Tags:
Amended Statement of Changes in Beneficial Ownership (4/a)
June 03 2020 - 04:35PM
Edgar (US Regulatory) Print
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
1. Name and Address of Reporting Person *
Al-Siddiq Waqaas 2. Issuer Name and Ticker or Trading Symbol
BIOTRICITY INC. [ BTCY ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__X__ Director __X__ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
CEO and President
(Last) (First) (Middle)
275 SHORELINE DRIVE, SUITE 150 3. Date of Earliest Transaction (MM/DD/YYYY)
4/7/2020
(Street)
REDWOOD CITY, CA 94065
(City) (State) (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
4/9/2020
6. Individual or Joint/Group Filing (Check Applicable Line)
_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 8. Price of Derivative Security
(Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Option (right to purchase) $1.06 4/7/2020 A 1400000 (1) 4/7/2025 Common Stock 1400000 $0 1400000 D
Explanation of Responses:
(1) The options vest quarterly over four years.
Remarks:
The Amended Form 4 is being filed to correct the expiration date and exercise price.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Al-Siddiq Waqaas
275 SHORELINE DRIVE, SUITE 150
REDWOOD CITY, CA 94065 X X CEO and President
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
1. Name and Address of Reporting Person *
Al-Siddiq Waqaas 2. Issuer Name and Ticker or Trading Symbol
BIOTRICITY INC. [ BTCY ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__X__ Director __X__ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
CEO and President
(Last) (First) (Middle)
275 SHORELINE DRIVE, SUITE 150 3. Date of Earliest Transaction (MM/DD/YYYY)
4/7/2020
(Street)
REDWOOD CITY, CA 94065
(City) (State) (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
6. Individual or Joint/Group Filing (Check Applicable Line)
_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 8. Price of Derivative Security
(Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Option (right to purchase) $0.98 4/7/2020 A 1400000 (1) 4/7/2030 Common Stock 1400000 $0 1400000 D
Explanation of Responses:
(1) The options vest quarterly over four years.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Al-Siddiq Waqaas
275 SHORELINE DRIVE, SUITE 150
REDWOOD CITY, CA 94065 X
REDWOOD CITY, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that world renown cardiologist Dr. John Simpson will serve as Chair of its Scientific & Medical Alliance Board. Dr. Simpson is credited with inventing and commercializing the first over-the-wire balloon catheter used for percutaneous transluminal coronary angioplasty (PTCA). This single invention created the field of interventional cardiology as it is known today. He joins an already impressive roster of advisory board members who support Biotricity’s research and development with a focus on scientific and clinical excellence.
Over the course of his storied medical technology career, Dr. Simpson has founded and successfully exited companies like ACS and DVI (both acquired by Eli Lilly), CVIS (acquired by Boston Scientific), Perclose (sold to Abbott), Lumend (acquired by Cordis), and Fox Hollow (acquired by ev3 which is now part of Medtronic). Dr. Simpson received his PhD in Immunology from the University of Texas, his MD from Duke University, and completed his fellowship in interventional cardiology at Stanford University. He is a member of the American College of Physicians, a fellow of the American College of Cardiology, has published on a wide variety of medical subjects, and has lectured extensively throughout the world.
“It is with great pleasure that we announce Dr. John Simpson’s new position as Chair of our Scientific & Medical Alliance Board,” said Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO. “Dr. Simpson’s extensive expertise in the medical technology sector will provide us with invaluable clinical insights and guidance as we continue to expand our product offerings.”
To learn more, visit www.biotricity.com or follow on:
Twitter: @biotricity_inc Facebook: facebook.com/biotricity/ or
LinkedIn: linkedin.com/company/biotricity-measuring-vitals
The Q 900 hundreds devices deployed for 3 months = 900 hundred times 400 times 3 = 1080000. Next Q 1500 devices out for 3 months = 1800000 . 1800000 tim s 4 Q’s = 7200000 a year . YES break even by next Q
REDWOOD CITY, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced calendar fourth quarter financial results for the three months which ended December 31, 2019.
FOURTH QUARTER HIGHLIGHTS
Revenues for the three months which ended December 31, 2019 grew by 225% compared to the corresponding prior year quarter;
Recurring technology fee revenues grew by more than 500% during the same period
COMMENTARY ON PERFORMANCE AND OUTLOOK
"Biotricity focuses on developing novel medical remote monitoring solutions with a recurring technology fee business model,” said Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO. “On a year-to-date basis, technology fee revenues grew by over 504% for the nine months which ended December 31, 2019 when compared to the corresponding prior year. The Company earned total revenue of $1.1 million, which is a 380% increase over the prior year. The total revenue results for the three-month period which ended December 31, 2019 corresponds to 96% of the revenues earned during the entire 12-month period of the Company’s fiscal year which ended March 31, 2019.”
On a net basis, the Company incurred losses of $2,371,003 (loss per share of 0.067) for the three months which ended December 31, 2019. Mr. Al-Siddiq commented, “During this period of initial Bioflux® commercialization, we are devoting significant resources to research and development.”
Biotricity CFO John Ayanoglou added, “Revenue growth for the three months which ended December 31, 2019 is particularly significant given seasonal lows that are anticipated. Our growth trajectory continues to improve, with total revenues increasing by 10.4% and recurring technology fee revenues increasing by 28% during this same period. Based on its current sales profile, at the margin, approximately 65% of Biotricity’s revenues are comprised of annual recurring revenues (ARR), and this component is expected to increase in both absolute and percentage terms into the future.”
“The Company’s expanding size and the quality of its salesforce has resulted in a rising ARR reach quarter,” said Dr. Al-Siddiq. “To do this, the Company continues to successfully attract non-dilutive sources of capital, such as its recent $8 million preferred share transaction. We have hired seasoned sales professionals, each with a history of introducing new cardiovascular technologies to the marketplace, and plan to continue to grow our sales force in the future.” Biotricity also announced that it is pursuing new FDA clearances for state-of-the-art technologies that it intends to bring to the market in the near future:
? Advanced ECG analysis software that can analyze and synthesize patient ECG monitoring data with the purpose of distilling it down to the important information that requires clinical intervention, significantly reducing costs;
? The Biotres patch solution, which will be an innovative product in the field of Holter monitoring, expanding our top and bottom-line revenues; and
? The Bioflux® 2.0, which is the next generation of our award winning Bioflux®, further expanding our revenue generating telemedicine product line-up.
By design, management established Biotricity’s horizontal technology platform to align with the Centers for Medicare and Medicaid Services (CMS) stated plan to cut over $57 billion in costs from US public healthcare spending, by moving unnecessary inpatient care to outpatient care, and focusing on RPM and preemptive diagnostics. This paradigm shift has the potential to improve patient care and save additional lives, while also lowering healthcare costs.
“The company has demonstrated continued growth, which is a testament to the strong work ethic of everyone on the Biotricity team,” said Dr. Al-Siddiq. “The efforts of our R&D staff to develop technologies which will require new FDA applications promises to enhance that trajectory and the revenue expansion that we have posted quarter over quarter.”
Management’s business outlook, and more detailed results for the three months which ended December 31, 2019, can be found in Management's Discussion and Analysis ("MD&A"), available on EDGAR and Biotricity's website.
To get to .25 cent a share earning , they need to have 3300 devices deployed , they already have more than 900 hundred devices deployed. This was with a few sales people and a soft launch in just a few states. They now are in more than 11 states and have went to full deployment, with many many more sales staff. The revenue is reoccurring each and every 2 weeks
IMO , short covering due to Q coming in a few weeks. They will be at break even this week or next. Their revenue is reoccurring. This time next year we should be at making a minimum of .25 cent earning per year. Companies in MT sector trade at 20 times earnings, that puts at 5 dollars a share. They are also going to summit for FDA approval at the end of February on the next generation for their device with AI .
ORLANDO, Fla., Jan. 29, 2020 (GLOBE NEWSWIRE) -- When we first published regarding medical diagnostic and consumer healthcare technology company Biotricity (BTCY) back in December, our focus was on the Company’s innovation and aspirations in the vast sensor market. As you may recall, we believe that the sensor market on the whole is a gamechanger like drones, cannabis, bit-coin, and the like. Mighty Forbes makes a compelling argument as to how technology could revolutionize preventative medicine.
We agree.
And a recent announcement from Biotricity puts the company ever closer to a real opportunity to participate in the compelling sensor market in a truly significant way. Just last week the Company announced that it is finalizing its FDA filing for its next generation, advanced ECG analysis software with an expectation to file a 510(k) application with the US FDA by the end of February 2020.
Without getting too pedestrian regarding the aforementioned application, essentially what a 510(K) is a premarket submission made to the FDA to demonstrate that the device to be marketed is at least as safe and effective, that is, substantially equivalent, to a legally marketed device that is not subject to premarket approval.
Biotricity is clearly at a precipice, now awaiting approval to enter a market expected to reach $1.8 billion by 2026. If approved, the Company’s product could be a game changer. This approval could help accelerate growth, which is already at triple digits year-over-year.
According to Biotricity, current, traditional ECG monitoring requires significant human oversight to review and sift through incoming patient data for the purposes of determining which data is actionable and relevant. As such, it is imperative for biotechnology companies to build software that can analyze and synthesize this data with the purpose of distilling it down to the important information that requires clinical intervention.
Biotricity’s new ECG Analysis Software is purposefully engineered to improve analytic performance and identify anomalies by parsing through data trends and pinpointing information from which actionable insights can be gleaned. When fully cleared and implemented, the new software will significantly reduce the current human capital requirements for such tasks, reducing analysis time from 5 minutes to 30 seconds.
It is not expected to take long for the FDA to render an opinion and for this company to discover just how quickly and with what products it gets to enter this highly attractive industry.
About Biotricity Inc.
Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com.
REDWOOD CITY, Calif., Jan. 22, 2020 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it is finalizing its FDA filing for its next generation, advanced ECG analysis software with an expectation to file a 510(k) clearance application with the US FDA by end of February 2020.
The global remote patient monitoring market is expected to reach $1.8 billion by 2026, and with this growth comes the inevitable deluge of data that will threaten to inundate healthcare professionals with a surplus of information, much of which will be non-actionable biometric data, wasting valuable time and resources.
Today, traditional ECG monitoring requires significant human oversight to review and sift through incoming patient data for the purposes of determining which data is actionable and relevant. As such, it is imperative for biotechnology companies to build software that can analyze and synthesize this data with the purpose of distilling it down to the important information that requires clinical intervention.
Biotricity’s new ECG Analysis Software is purposefully engineered to improve analytic performance and identify anomalies by parsing through data trends and pinpointing information from which actionable insights can be gleaned. When fully cleared and implemented, the new software will significantly reduce the current human capital requirements for such tasks, reducing analysis time from 5 minutes to 30 seconds. This tenfold improvement will allow the company to divert valuable human resources to more high-level operations.
“Our advanced software is going to drive scalability up while driving costs down,” said Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO. “Our software will preclude the ongoing challenges that many healthcare professionals face when it comes to a surplus of patient data – with our technology, we will be able to improve data analytics so that doctors can benefit from receiving patient information that actually requires their attention and intervention.”
The Company’s flagship product, Bioflux®, is a complete solution for cardiac monitoring and diagnosis, consisting of the Bioflux® device, proprietary software, and a 24/7 monitoring center that merges seamlessly with physicians’ existing platforms and workflows. Unlike traditional cardiac monitoring solutions, Bioflux® extends the support a patient receives at a care facility into the patient’s home. The device monitors a patient’s ECG in near real-time, constantly analyzing and collecting data on the device and periodically uploading to the cloud via embedded cellular technology. In cases where anomalies or emergencies are detected, the data is transferred to a call center for appropriate action
REDWOOD CITY, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it has converted approximately $1.8 million in debt investment from long-term private investors into its recent Preferred Equity transaction, bringing the cumulative total sold in this round to $7.8 million. This conversion further expands the company’s runway.
The conversion comes at an important time and is structured to reduce Biotricity’s short-term cash flow obligations, expand its runway, and benefit its execution strategy. This investment is another step for the company’s broader goal to gain a listing on a senior stock market exchange.
Biotricity is focused on growth and the expansion of its product portfolio. The capital raised, alongside with the revenues that the company currently generates, provides Biotricity with working capital to accomplish its goals for the coming year. Among other important initiatives, this capital infusion will be used to engage on the following priorities:
Growth and doubling of the company’s sales force;
FDA filing for Biotres patch solution within the first 6 months of 2020, which will be a novel product in the field of Holter monitoring;
FDA filing for Bioflux 2.0, the next generation of our award winning Bioflux® device.
“By converting this obligation, we are continuing to strengthen the financial position of the Company,” said Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity. “By structuring and implementing this conversion, we focused on reducing our shorter-term obligations in order to establish a stronger foundation for growth. We look forward to 2020 and our continued pursuit and execution of sales and technology milestones. We are grateful to our long-term investors for their support in Biotricity’s mission and the value it brings to the future of healthcare.
Biotricity Completes Development of its ECG Patch Platform
Company Prepares for FDA Filing of New Device
REDWOOD CITY, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it has completed development of its ECG patch platform. An extension of the company's award-winning Bioflux(R) device, Biopatch is ideal for patients with less complicated cardiac conditions. The patch leverages the advanced diagnostic capabilities of Bioflux(R) in a miniaturized form factor with 3 standard electrodes but no lead wires. It provides wireless communication to enable real-time monitoring for patients who are either at risk for, or diagnosed with, certain cardiac issues. The patch is currently undergoing internal clinical testing; once testing is complete the company will file a 510(k) clearance application with the US FDA.
"With development of the patch completed, we've achieved the most significant milestone in bringing our product to the market," said Mr. Waqaas Al-Siddiq, Founder and CEO of Biotricity. "We took special care to develop our patch platform to ensure that our solution overcomes all of the limitations that other ECG patches in the market currently have. It's with great pride that I can affirm that we have done exactly that. Biopatch will allow us to widen our commercial reach, offering patients a more convenient monitoring solution without compromising diagnostic quality."
The company's flagship product Bioflux(R) already offers advanced diagnostics for ambulatory patients and patients who are at high risk for adverse heart effects. A miniaturized application of the Bioflux(R) technology, Biopatch extends the same advanced diagnostics while offering patients a more convenient, less cumbersome monitoring solution to encourage greater user compliance.
Biopatch Key Features
-- 3-channel solution, industry-recommended for best diagnostic yield
-- Compact and comfortable with high usability
-- A 3-in-1 solution offering Event, Holter, and Extended Holter monitoring;
future extension will allow for mobile cardiac telemetry (MCT) monitoring
-- Wireless communication to enable real-time monitoring
-- Ensures advanced conduction & flexibility for all skin types, designed to
use standard electrodes
-- Automated wireless uploading addresses diagnostic and report turn-around
issues that current patches face
-- Rechargeable to address battery limitations that other patches in the
market currently face
Continuous ECG monitoring patches that patients wear at home have been found to significantly increase detection of atrial fibrillation (AF), according to an industry-funded study in JAMA. AF can lead to serious heart-related complications, including stroke and heart failure. Small, comfortable, and effective, Biopatch will ensure patients with AF and other cardiac issues receive early diagnosis and preemptive care from their physicians
Btcy charges 200 dollars a read . A read is 2 weeks, that’s 400 dollars every month per device. The revenue from the read is reoccurring each and every month. Btcy also sells these devices at 175 per device , which is a one time charge.In their filling they have reported 900 hundred devices deployed. 3 months , 1 Q, of charges for 900 hundred devices is 1,080,000 . The revenue will show up on their Q 3 months later. A years worth of revenue is at 4,320,000 already . This is reoccurring each and every year. Don’t forget about the devices sales for those not cooled yet. Since we have went from soft lunch to full lunch just a short time ago , we went from 300 devices to 900 . What do you think we will be at a year from now with derives deployed and collecting revenue. You know that the shorts are toast. Simple math and facts prove me right . The challenge sent before you is PROVE me wrong with numbers and facts.
It is an exciting time in the world of digital health! The Centers for Medicare and Medicaid Services (CMS) has released its final 2020 rules, which directly impacts remote patient monitoring (RPM) services. This falls on the heels of 2019's reimbursement changes for providers using RPM under the following CPT Codes: CPT 99453, CPT99454, and CPT 99457.
Digital health companies have been anticipating these changes with an understanding of how they can improve the adoption of RPM as well as the health of their patients. The addition of these CPT codes allows for a greater flexibility for providers that opt to utilize RPM services for the patients they serve.
The two changes that were recently finalized include allowing RPM to be provided “incident to” under general supervision, and for CPT Code 99458 to be used as an add-on code for patients who received an additional 20 minutes of RPM services in a given month. Both new rules will go into effect on January 1, 2020.
cpt-code-graph
“Incident to” billing of CPT Code 99457
When the CPT codes for RPM were created earlier this year, the CMS stated that RPM services could only be delivered by a physician and not by an “auxiliary personnel incident to the practitioner’s professional services.” An “incident to” service is defined as a service rendered under the supervision of a physician and/or qualified health care professional and then billed to Medicare in the name of the physician and/or qualified healthcare professional.
In April of 2019, the CMS stated that it would allow for “incident to” billing by auxiliary personnel if they were under direct supervision, which meant they were in the same building at the very same time. This new rule allows for general supervision instead of the direct supervision that was required prior to April of 2019; thus, CPT codes 99457 and 99458 can be billed under general rather than direct supervision.
General supervision allows physicians to use telemedicine to conduct general supervision with their auxiliary staff. Furthermore, this rule states that the physician and/or other qualified healthcare professional who is supervising auxiliary staff does not have to treat the patient receiving RPM services, yet the supervising physician/qualified healthcare professional can bill Medicare for the “incident to services”.
This rule extends the flexibility of the RPM services and does not exclusively put the burden solely on the physician and/or qualified healthcare professional. This rule will change the landscape of the current business models being used for RPM services and will enhance them greatly.
New RPM Code for Extra 20 Minutes
The CMS also created a new rule that will allow for billing after the first 20 minutes of RPM services, which is currently billed under CPT 99457. Patients who received an additional 20 minutes of RPM services and require interactive communication with clinical staff/physician/qualified healthcare professional can be billed under CPT code 99458. It's estimated that reimbursement will be at the rate of approximately $43 per month.
In conclusion, these new rules and CPT codes demonstrate that the CMS recognizes the importance of RPM services and its power to minimize the gaps in our current healthcare system. All patients can benefit from these services and these changes will certainly increase providers’ chances to adopt a medical model that includes RPM services.
This sums up their last Q ,300 devices deployed and revenue from 3 months use PLUS device sales. The next Q 300 devices which generated 3 months of revenue but not device sales. Then in Q 2 they had some dives collecting revenue but not devices sales, some collecting revenue plus devices sales, and some deployed but you can’t collect revenue until they are already used. I work 2 weeks but only get paid one the third week for 2 weeks worth of work get it. Even if you don’t understand the math you should understand this , Q1 345906 dollars collected, Q2 672906 dollars collected. Next Q you can’t count revenue plus devices sales for 900 devices. I understand the math and timeframe and predict around 900000 to 1.1 million for next Q and the Q after that 900 units collecting revenue, device sales already counted from the Q before. 1.4 to 1.6 million dollars. This same time next year we will be slightly above break even. I was look for a little over 500000 in the Q , I like many others forgot to account for the 3 month needed for the device to be in use to get the revenue on the books. So we were 172000 dollars past what I predicted.
During the first year of this limited market release, by March 31, 2019, we sold approximately 300 devices, which were used to perform MCT studies on patents, such that the Company earned combined device sales and technology fee income totally $398,200. Based on our success, in April 2019, we decided to expand sales of the product beyond limited release by doubling the size of our salesforce and our geographic footprint to 11 US states, and the sales pipeline of our product has begun to grow.
In line with its strategy, during the six months ended September 30, 2019, Biotricity almost tripled its fleet of remote patient monitoring devices from the levels of its most recent fiscal year-end, which was March 31, 2019. Biotricity had deployed more than 900 devices as at September 30, 2019. This has resulted in combined device sales and technology fee revenues of $345,906 and $672,906 for the respective three- and six-month periods then ended
CMS proposed two significant changes to remote patient monitoring (RPM) services reimbursed under the Medicare program. The changes, part of the proposed 2020 Physician Fee Schedule, have been hotly anticipated by digital health providers hoping to see more clarity and flexibility for RPM services.
The creation of new RPM codes at the beginning of 2019 (CPT Codes 99457, 99454, and 99453) was a big step forward to expanding patient digital health and improve health care delivery, outcomes, and cost management. Questions remained on how to properly use and bill the new RPM codes, and what business and staffing models are required by Medicare. Providers asked if RPM must be billed incident to a professional’s services under direct supervision, or if they could use general supervision similar to Chronic Care Management (CCM) services? What types of RPM devices are covered under the practice expense codes of CPT Codes 99454 and 99453? May patients manually enter data into a RPM device? And why is CPT Code 99454 billed on 30 day cycle while CPT Code 99457 is billed on a monthly basis? While CMS did not address all of these questions in the proposed Physician Fee Schedule rule, it did offer some helpful clarity and propose expanding Medicare RPM services in two significant ways: 1) allowing RPM to be delivered under general supervision; and 2) creating a new add-on code for patients who receive more than 20 minutes per month of RPM services.
RPM Can Be Delivered Under General Supervision
This is arguably the single most important and beneficial change for digital health in the entire proposed 2020 Physician Fee Schedule. When CMS first created the RPM codes, they stated RPM could not be delivered incident to, reasoning that CPT code 99457 describes professional time and “therefore cannot be furnished by auxiliary personnel incident to a practitioner’s professional services.” An incident to service is one that is performed under the supervision of a physician (broadly defined), and billed to Medicare in the name of the physician, subject to certain requirements. Subsequently, CMS issued a technical correction allowing incident to billing of RPM services by auxiliary personnel under direct supervision. Direct supervision means the physician and auxiliary personnel must be in the same building at the same time (albeit not the same room). General supervision, in contrast, does not require the physician and auxiliary personnel to be in the same building at the same time, and the physician could instead use telemedicine to exert general supervision over the auxiliary personnel.
Industry insiders advocated for changing the RPM rules to expressly allow incident to billing of RPM under general supervision and CMS concurred. Under the proposed rule, RPM services reported with CPT codes 99457 and 994X0 may now be furnished under general supervision rather than the currently required direct supervision. The physician or other qualified healthcare professional supervising the auxiliary personnel need not be the same individual treating the patient more broadly. However, only the supervising physician or other qualified health care professional may bill Medicare for the incident to services.
Changing the RPM rules to expressly allow incident to billing of CPT code 99457 under general supervision greatly expands the potential operations and business models associated with RPM services, thereby allowing more patients to enjoy the quality-improving benefits of remote patient monitoring.
New RPM Code for Extra Minutes
CMS has also proposed changing CPT code 99457 to only cover the initial 20 minutes of monitoring services, while a new CPT code 994X0 would be used as an add-on code for those patients who receive additional 20 minutes intervals of RPM. CMS did not address how often the new add-on code 994X0 can be billed per month, or if there is a maximum limit. CMS has proposed a work RVU of 0.50 and direct PE inputs for the new add-on code. The proposed code descriptions are as follows:
CPT code 99457 (Remote physiologic monitoring treatment management services, clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month; initial 20 minutes)
New CPT code 994X0 (Remote physiologic monitoring treatment management services, clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month; additional 20 minutes)
BTCY have 650 devices deployed, at 300 hundred dollars a read.A read is 2 times a month. 600 dollars a month times 650 devices is 390000 dollars a month. 390000 times 12 months = 4680000 dollars a year. 4.68 million a year that is recurring every year. BTCY can easily double the 650 devices in a year possible triple. That’s 9.36 million to 14 million a year recurring every year . 9 million a year minus 7 million burn rate leaves 2 million. 2 million divided by 35 million is about 6 cent a share. 6 cent times , 20 times earnings = 1.20 cent . At 14 million it would equal 4 dollars . We are way under valued. Once off the OTC , double the 20 times earnings and you get 2.40 to 8 dollars a share.
Shorts are still shorting big time, it’s so funny they’re digging them a bigger hole. I understand the hole must be big enough to bury John scam, Crescent, eddypgil just to name a few. Short interest for the 27 Aug 27
NA
NA
NA
18,818 total shares sold
14,334 total shares shorted. 76.17 percent short
76.17
Short interest for yesterday. Date
Close
High
Low
Volume
Short Volume
% of Vol Shorted
Aug 09
NA
NA
NA
50,460 total volume
11,715 total short shares sold . 23.22 percent
23.22
Again large short volume for yesterday.
Close
High
Low
Volume
Short Volume
% of Vol Shorted
Aug 07
NA
NA
NA
5,860 total volume
4,000 short volume 68. 25 percent
Recent short
68.26
Wow Hugh short interest yesterday.
Close
High
Low
Volume
Short Volume
% of Vol Shorted
Aug 06
NA
NA
NA
5,298 total volume
4,098 total short volume, 77.35 percent
77.35
Date Close High Low Volume Short Volume % of Vol Shorted
Aug 02 NA NA NA 16,265 3,405 20.93